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Summary
Background: Aspirin and anti-platelet drugs are used commonly for patients with
coronary heart disease. Proton pump inhibitor (PPI) and high-dose H2-blocker were
recommended for preventing NSAIDs-related ulcer. Previously H2-blocker reported
to have some negative cardiovascular effects. Additionally, a recent in vitro study
showed that PPI reduced cardiac contractility. In this study, we evaluated whether
chronic administration of PPI and high-dose H2-blocker affects left ventricular func-
tion.
Method: Fifty-two stable angina patients were enrolled and classiﬁed into PPI
group ([P]; lansoprazole: 15mg/day, n = 28), H2-blocker group ([H]; famotidine:
40mg/day, n = 8), and control ([C]; none or mucosal-defense drug, n = 16). Eligible
patients showed normal cardiac function in initial catheterization without admin-
istrated PPI or H2-blocker. They received percutaneous coronary intervention and
follow-up catheterization. We compared changes in ejection fraction (EF: %), end
diastolic/systolic volume index (EDVI/ESVI: ml/m2), and peak positive/negative
dp/dt (±dp/dt: mmHg/s) in left ventricular angiography series.
Result: There were no signiﬁcant differences among three groups regarding patient
characteristics, backgrounds of angiographic and intervention, except for fewer
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smokers in [C]. Other drugs such as - and Ca-blocker did not have effects on cardiac
function except for aspirin during 255± 115 days follow-up. Rate of EF changes signif-
icantly decreased in [P], and tended to decrease in [H] (C: 3.8± 9.8%, H: −1.6± 7.6%,
P: −2.1± 5.9%; p < 0.05 for [C] vs. [P]). Those of ESVI changes were signiﬁcantly
greater in [P], and tended to be greater in [H] (C: −4.5± 16.2%, H: 4.9± 15.5%, P:
7.3± 16.2%; p < 0.05 for [C] vs. [P]), though, EDVI changes’ were similar (C: 2.5± 8.9%,
H: 2.6± 3.6%, P: 1.6± 6.1%; p = ns). Rate of ±dp/dt—–changes tended to decrease
in [H] (+dp/dt: C: 3.9± 15.5%, H: −10.0± 25.2%, P: 0.3± 19.6%; p = ns, −dp/dt: C:
−0.1± 19.5%, H: −8.5± 20.4%, P: 5.7± 27.7%; p = ns).
Conclusion: In this study, PPI and high-dose H2-blocker have EF-reducing tendency.
However, these changes were small and these drugs seemed to exhibit little inﬂuence
clinically.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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abnormal wall motions such as asynergy or diffuse
hypokinesis. A total of 58 patients fulﬁlled the eli-
gibility criteria: 32 patients with PPI (lansoprazole© 2008 Japanese Colleg
reserved.
Introduction
Aspirin and other anti-platelet drugs are essential
to patients with ischemic heart disease [1,2]. The
long-term use of these drugs can potentially lead
to non-steroidal anti-inﬂammatory drugs (NSAIDs)-
related peptic ulcer [3]. Proton pump inhibitor
(PPI), high-dose H2-blocker, and prostaglandins are
recommended for the prevention of such aspirin-
or NSAIDs-related peptic ulcers [3], and these
drugs are normally administrated to patients with
ischemic heart disease including stable angina that
have received percutaneous coronary intervention
(PCI).
In a previous report, the use of high-dose H2-
blocker was associated with several adverse effects
such as bradycardia, sinus arrest, atrio-ventricular
conduction disturbances, and cardiac decompen-
sation [4]. However, another study reported that
H2-blocker could modulate heart-rate variability,
and has the possibility to inhibit the increase
in the sinus rate and prevent ventricular ectopy
[5].
Although PPI (omeprazole) administration did
not lead to any changes in the cardiac perfor-
mance of patients with congestive heart disease,
as measured by impedance cardiography and
mechanocardiography, after 1-week oral treatment
with therapeutic doses compared with H2-blocker
(famotidine) [6], PPI (pantoprazole) depresses car-
diac contractility at higher concentrations in vitro
by depressing Ca2+ signaling and myoﬁlament activ-
ity [7].
It remains unclear in clinical practice, however,
whether this negative effect on cardiac perfor-
mance is attributable to long-term administrations
of PPI and high-dose H2-blocker, and cardiac effects
of these drugs assessed by invasive study have
scarcely repoted. The purpose of this study was to
investigate cardiac function in patients with stable
1
1
8
ongina using left ventricular (LV) angiography, and
e compared pre-drug administration and post-PCI
ollow-up results.
aterials and methods
atient selection
he present study was conducted according to
he principles of the Declaration of Helsinki and
pproved by the local Ethics Committee. All study
articipants gave informed consent.
Patient selections are summarized in Fig. 1.
hree hundred and ﬁfty-ﬁve patients underwent
lective PCI in our institute between June 2004
nd March 2007. Patients were considered eligible
or this study if: they had never undergone a car-
iac catheterization study nor been administrated
PI or H2-blocker; had a history of stable angina
r signs of myocardial ischemia in the presence of
ngiographically signiﬁcant stenosis (>75%) in one
r more coronary vessels; and had received PCI
nd undergone re-catheterization study involving
V angiography in a series of study.
Clinical exclusion criteria included: acute coro-
ary syndrome, a history of unstable angina,
yocardial infarction, and prior revascularization
uch as PCI or coronary artery bypass graft. Angio-
raphic exclusion criteria included lesions requiring
oronary artery bypass graft such as an unpro-
ected left main trunk, lesions containing thrombi,
nd when left ventricular angiography revealed5mg: 28; omeorazole 20mg: 3; rabeprazole 10mg:
), 10 patients with H2-blocker (famoidine 40mg:
; ranitidine 5mg: 1; nizatidine 150mg: 1) and 16
thers (none: 13; other mucosal-defense drug: 3).
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lFigure 1 Flow cha
e classiﬁed patients into group P (lansoprazole
5mg: n = 28), group H (famoidine 40mg: n = 8), and
ontrol (group C: n = 16).
rocedures and antithrombotic treatment
ll patients received oral therapy consisting of
00mg of ticlopidine twice plus 81mg of aspirin
aily from 4 weeks before procedures, indeﬁnitely.
ases in which ticlopidine was contraindicated
eceived 100mg of cilostazole twice. Following
atheterization, all patients started to receive
anagement with intensive pharmacotheraphy and
ifestyle modiﬁcation before PCI.
PCI was performed according to the standard
rotocol, based on angiographic and intravascular
ltrasound ﬁndings. During intervention, patients
eceived intravenous heparin (7000U) followed by
000U of heparin every 60min.
V volume and pressure
V angiography (30◦ right anterior oblique, 60◦ left
nterior oblique) was performed just before coro-
ary angiography. LV volumes were obtained by
he biplane area—length method [8], via which
nd diastolic volume, end systolic volume, and
jection fraction (EF: %) were calculated. The
nd diastolic volume index (EDVI: ml/m2) and end
m
c
P
tpatient selection.
ystolic volume index (ESVI: ml/m2) were also
alculated by dividing the end diastolic and end
ystolic volumes by the body surface area, respec-
ively.
LV pressure was recorded in each patient with
pigtail catheter. The baseline was calibrated
lectronically by a transducer control unit before
atheter insertion, and zero shift was adjusted to
he level of the mid-chest position.
All cases showed a normal sinus rhythm, and
ve consecutive complexes were averaged to
eterminate ratio of change of ventricular pres-
ure to change in time (peak positive dp/dt:
dp/dt: mmHg/s; peak negative dp/dt: −dp/dt:
mHg/s).
tatistical analysis
ategorical variables were compared using the
2 and Fisher’s exact tests. Continuous variables
ere compared using t-tests. Categorical data
re expressed as frequencies and percentages. p-
alues < 0.05 were considered signiﬁcant.
Repeated-measures ANOVA was used to ana-
yze the effect on EF, EDVI, ESVI, +dp/dt, and
agnitudious of −dp/dt. These were chosen as out-
ome variables, and predictor variables included
atient characteristics, angiographic and interven-
ion backgrounds, and adjunct drugs.
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Results
Characteristics of patients
Patient characteristics are summarized in Table 1.
Among all patients, the mean age was 65 years; 64%
were men; 73% had hypertension; 54% had hyper-
lipidemia; and 37% had diabetes. Although 27% of all
patients were smokers, only 1 patient in the control
group smoked.
Angiographic and intervention factors
Angiographic and intervention factors also are sum-
marized in Table 1. Twenty-ﬁve patients (48.1%) had
multi-vessel diseases, but only 7 patients (13.5%)
requiring treatment for multi-vessels according
to myocardial ischemia. The majority (53.8%) of
treated lesions were located left anterior descend-
ing artery, with each group showing a similar
tendency. Bare metal stents were employed in
53.8%, drug eluting stents in 36.5%, and no stent
was applied 9.6%; these trends were also similar in
each group.
Medication and treatment
Before catheterization, patients had only received
drugs for each disorder regarding coronary risk
factor, and less than 30% of patients received
anti-platelet therapy. One patient who did not
receive aspirin had a history of aspirin-induced
drug eruption, and only received ticlopidine. Eight
patients underwent ticlopidine discontinuation,
because of drug eruption or liver damage induced
by it, 7 patients changed to cilostazol, and one
patient was administered a double-dose of aspirin.
Patients exhibited a high rate of receiving multiple,
evidenced-based therapies [1] (Table 2).
Clinical outcomes
In this study population, there was no peripro-
cedural complication such as death, myocardial
infarction, acute or subuacte stent thrombus, or
repeat PCI. Overall, the follow-up period 255± 115
days, with no signiﬁcant difference among 3 groups.
There were no out-of-hospital cardiac events
such as target lesion revascularization. Further,
no patients experienced gastro-intestinal hemor-
rhage.LV volume and pressure
Table 3 shows data on LV volume and pressure.
LV volume and pressure revealed no signiﬁcant
i
a
h
s
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ifference between baseline and follow-up data
mong the 3 groups. We also investigated rate
f changes in LV volume and pressure in each
roup (Fig. 2). The rate of changes in EF in group
showed signiﬁcantly greater decrease than in
he control group (C: 3.8± 9.8%, P: −2.1± 5.9%,
< 0.05), and that in group H showed a decreas-
ng tendency (H: −1.6± 7.6%, ns compared to
ontrol). The change rate of ESVI in group P
howed was signiﬁcantly greater increase than
hat in the control group (C: −4.5± 16.2%, P:
.3± 16.2%, p < 0.05), and that in group H showed
n increasing tendency (H: 4.9± 15.5%, ns com-
ared to control). The rate of changes in EDVI
ere similar among three groups (C: 2.5± 8.9%, H:
.6± 3.6%, and P: 1.6± 6.1%, ns). The rate changes
n +dp/dt and magnitudious −dp/dt revealed
o signiﬁcant differences among the 3 groups.
owever, these parameters showed a decreasing
endency in H group (+dp/dt: C: 3.9± 15.5%, H:
10.0± 25.2%, and P: 0.3± 19.6%, magnitudious
dp/dt: C: −0.1± 19.5%, H: −8.5± 20.4%, and P:
.7± 27.7%).
ther factors related to changes in LV
olume and pressure
able 4 shows the relationships between LV volume,
ressure, and other variables: patients character-
stics, angiographic and intervention backgrounds,
nd adjunct drugs. Multi-vessel PCI was signif-
cantly correlated with EF and ESVI. RCA and
dp/dt were also signiﬁcantly correlated. Regard-
ng adjunct drugs, only aspirin was associated with
dp/dt. However, these variables showed similar
verall tendency in this study.
iscussion
he present ﬁndings indicated that: (1) chronic
dministration of PPI could signiﬁcantly decrease
he rate of changes in EF, increase that in ESVI com-
ared with the control; (2) high-dose H2-blocker
dministration tended to decrease the rate of
hanges in EF, increase that in ESVI compared with
he control, and also tended to decrease that in
he magnitude of positive dp/dt and magnitudious
f negative dp/dt; (3) other drugs except for aspirin
o not effect the change in cardiac function.
Patients with ischemic heart disease requirentensive treatment including therapies involving
spirin and anti-platelet [1,2]. Especially, ischemic
eart disease patients receiving PCI with coronary
tent must continue taking aspirin, ticlopidine or
lopidogrel [1,2,9,10]. NSAIDs-related ulcer should
Cardiac
effect
of
PPIand
H
2-blocker
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Table 1 Patients’ characteristics, angiographic and intervention backgrounds
Total (%) Control (%) p (%) H (%) p-Value
n 52 16 28 8
Patients’ characteristic
Age (y.o.) 65.1± 9.5 62.5± 7.4 662± 11.8 66.3± 5.3
Male 33 63.5 11 68.8 17 60.7 5 62.5 ns
Diabetes mellitus 19 36.5 9 56.3 3 10.7 7 87.5 ns
Hypertension 38 73.1 13 81.3 17 60.7 8 100.0 ns
Hyperlipidemia 28 53.5 9 56.3 17 60.7 2 25.0 ns
Smoker 14 26.9 1 63 11 39.3 2 25.0 p< 0.05
Angiographic and intervention background
Single vessel disease 27 51.9 5 31.3 18 64.3 4 50.0 ns
Two vessel disease 12 23.1 5 31.3 5 17.9 2 25.0 ns
Three vessel disease 13 25.0 6 37.5 5 17.9 2 25.0 ns
Multi-vessel intervention 7 13.5 3 18.8 3 10.7 1 12.5 ns
Target vessel
Left anterior descending 28 53.8 8 50.0 15 53.6 5 62.5 ns
Left circumﬂex 16 30.8 6 37.5 8 28.6 2 25.0 ns
Right 18 34.6 6 37.5 10 35.7 2 25.0 ns
Intervention device
Drug eluting stent 19 36.5 5 31.3 10 35.7 4 50.0 ns
Bare metal stent 28 53.8 11 65.8 15 53.6 2 25.0 ns
POBA or CB alone 5 9.6 0 0.0 3 10.7 2 25.0 ns
Follow-up period (days) 255± 115 288± 158 238± 100 252± 53 ns
Ages and follow-up days are expressed as the mean± S.D. POBA: plain old balloon angioplasty; CB: cutting balloon angioplasty. There was a signiﬁcant difference in the number of
smokers between the control and group P (p < 0.05).
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Table 2 Prescribed drugs
Previous prescribed drug Adjunct drugs Prescribed drugs at follow-up
Total Control P H Total Control P H Total Control P H
n 52 16 28 8 52 16 28 8 52 16 28 8
Asprin 11 5 4 2 40 10 24 6 51 15 28 8
Ticlopidine 2 1 1 0 41 13 24 4 43 14 25 4
Cilostazol 2 1 1 0 5 1 1 3 7 2 2 3
-Blocker 5 3 2 0 3 0 2 1 8 3 4 1
-Blocker 2 1 1 0 1 0 1 0 3 1 2 0
Ca-blocker 25 11 10 4 6 0 6 0 31 11 16 4
ARB/ACE 23 7 10 6 6 1 4 1 29 8 14 7
Statin 13 6 5 2 9 1 8 0 22 7 13 2
Fibrate 1 0 0 1 2 1 1 0 3 1 1 1
Nicorandil 8 5 2 1 15 3 11 1 23 8 13 2
Nitrate 7 2 4 1 11 3 6 2 18 5 10 3
Diuretics 5 4 1 0 3 2 1 0 8 6 2 0
Insulin 8 4 2 1 0 0 0 0 7 4 2 1
-GI 8 4 2 2 0 0 0 0 8 4 2 2
Sulforrlurea 7 1 4 2 0 0 0 0 7 1 4 2
0
0
ing e
e
b
r
t
sMetformin 6 3 3 0 0
Pioglitazone 1 1 0 0 0
ARB: angiotensin II receptor blocker; ACE: angiotensin convert
be prevented because its development may lead
to the necessity to discontinue anti-platelet ther-
apy. PPI and high-dose H2-blocker, even though
their adverse cardiac effects were reported pre-
viously [4,7], are currently applied to prevent
NSAIDs-related ulcer. Generally, many cardiologists
are unaware of the negative aspects of PPI and
high-dose H2-blocker. Although in vitro study of H2-
blocker and PPI [4,7] and an a short-term, human,
in vivo study documented negative cardiovascular
i
m
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Table 3 LV volume and pressure assessed by left ventricul
Total Control
EF (%)
Baseline 70.5 ± 8.0 67.9 ± 1
Follow-up 70.0 ± 7.0 69.7 ± 9
EDVI (ml/m2)
Baseline 79.2 ± 13.5 77.5 ± 1
Follow-up 80.7 ± 13.2 79.9 ± 1
ESVI (ml/m2)
Baseline 23.5 ± 7.7 25.3 ± 1
Follow-up 23.9 ± 7.1 23.9 ± 9
+dp/dt (mmHg/s)
Baseline 2252 ± 592 2184 ± 6
Follow-up 2213 ± 554 2258 ± 5
Magnitudious −dp/dt (mmHg/s)
Baseline 2440 ± 555 2433 ± 6
Follow-up 2413 ± 550 2404 ± 6
Data are the mean± S.D. There were no signiﬁcant differences amon0 0 6 3 3 0
0 0 1 1 0 0
nzyme inhibitor; -GI: -glucosidase inhibitor.
ffect [6,7], the cardiac effects of PPI and H2-
locker on long-term administration have scarcely
eported.
H+/K+-ATPase could contribute signiﬁcantly to
he regulation of myocardial K+ and H+ homeosta-
is. The inhibition of H+/K+-ATPase might therefore
nduce cellular acidosis, which is known to inhibit
yocardial contractility mainly at the level of the
yoﬁlament. Schillinger et al. assessed this neg-
tive inotropic effect using pantoplazole in vitro
ar angiography
H P
0.6 68.9 ± 7.7 72.4 ± 5.8
.1 67.8 ± 8.7 70.7 ± 5.1
4.7 77.1 ± 13.5 80.7 ± 13.1
6.6 79.0 ± 13.4 81.6 ± 11.6
0.6 23.6 ± 5.7 22.4 ± 6.1
.3 24.8 ± 7.6 23.6 ± 5.8
45 2194 ± 80 2305 ± 623
05 1944 ± 439 2264 ± 587
07 2470 ± 403 2436 ± 580
69 2221 ± 439 2478 ± 512
g the 3 groups, as well as between the baseline and follow-up.
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Figure 2 Comparison of rate of changes in LV volume and pressure among the 3 groups. Bars represent the mean± S.D.
of each parameter with changes between baseline and follow-up. (A) The rate of change in EF. The values were:
3.8± 9.8% for the control, −1.6± 7.6% for group H, and −2.1± 5.9% for group P. There were signiﬁcant differences
between the control and group P. (B) The rate of change in EDVI. The values were: 2.5± 8.9% for the control, 2.6± 3.6%
for group H, and 1.6± 6.1% for group. There were no differences among the 3 groups. (C) The rate of change in ESVI. The
values were: −4.5± 16.2% for the control, 4.9± 15.5% for group H, and 7.3± 16.2% for group P. There were signiﬁcant
difference between the control and group P. (D) The rate of change in +dp/dt. The values were 3.9± 15.5% for the
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Aontrol, −10.0± 25.2% for group H, and 0.3± 19.6% for
roups. (E) The rate of change in maginitudious —dp/dt.
or group H, and 5.7± 27.7% for group P.
7]. In that work, a concentration of 6.25g/ml
nduced a reduction of the contractile force of iso-
ated trabeculae by 27± 9%, which is similar to the
linical concentration of 4.6g/ml due to 40mg
antoprazole [11] commonly orally administration.
atashima et al. reported that pantoplazole exhib-
ted a slightly weaker inhibition of acid secretion
han lansoplazole [12]. They also showed that the
elation between the plasma concentration and
nhibitory effect on PPIs could be assessed by phar-
acokinetic/pharmacodynamic analysis, and the
hronic administration of PPI could stabilized the
cid inhibitory rate to some extent. Though the
oncentration of pantoplazole (15mg) was half
f that previously applied (30mg) [13], a previ-
usly report showed that 15mg lansoprazole could
nhibit NSAIDs-related ulcer development as effec-
i
a
t
ip P. There were no signiﬁcant differences among the 3
values were −0.1± 19.5% for the control, −8.5± 20.4%
ively as 30mg [14]. It may be that lansoplazole
as a stronger H+/K+-ATPase inhibitor than pan-
oplazole, leading to a negative effect on cardiac
unction. However, the mean rate of change in
F was −2.1%, and that of ESVI was 7.3%. These
ere smaller decreases than predicted by an in
itro study, suggesting that the chronic administra-
ion of lansoplazole affects cardiac function only
lightly. One reason is that PPI also exhibits a pos-
tive inotropic effect in atria. Yenisehirli and Onur
bserved this effect of PPI in rat atria, and that it
as potentiated by pretreatment with the Na+/K+-
TPase inhibitor ouabain. Moreover, lansoprazole
nduced a prolongation of the action potential. The
uthors speculated that this could be mediated by
he inhibition of H+/K+-ATPase, promoting altered
ntracellular Ca2+ movement [15].
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Table 4 Variables of repeated-measures ANOVA
EF EDVI ESVI +dp/dt −dp/dt
Patients’ characteristics
Age (y.o.) 0.49 0.31 0.71 0.02 0.81
Male 0.29 0.53 0.13 0.78 0.46
Diabetes mellitus 0.57 0.40 0.43 0.79 0.6
Hypertension 0.94 <0.05 0.89 0.49 0.37
Hyperlipidemia 0.75 0.23 0.71 0.6 0.43
Smoker 0.39 0.79 0.21 0.68 0.98
Angiographic and intervention background
Single vessel disease 0.28 0.48 0.41 0.67 0.22
Two vessel disease 0.62 0.61 0.74 0.31 0.52
Three vessel disease 0.43 0.74 0.52 0.92 0.74
Multi-vessel intervention <0.01 0.42 <0.01 0.83 0.54
Target vessel
Left anterior descending 0.59 0.73 0.75 0.2 0.12
Left circumﬂex 0.19 0.52 0.47 0.28 0.5
Right 0.24 0.89 0.12 <0.05 0.07
Intervention device
Drug eluting stent 0.42 0.99 0.55 0.65 0.34
Bare metal stent 0.16 0.72 0.20 0.4 0.94
POBA or CB alone 0.38 0.55 0.28 0.27 0.3
Adjunct drug
PPI/H2-blocker 0.07 0.82 0.08 0.36 0.43
Asprin 0.53 0.94 0.55 <0.05 0.82
Ticlopidine 0.86 0.44 0.63 0.7 0.92
Cilostazol 0.75 0.58 0.94 0.14 0.19
-Blocker 0.07 0.74 0.07 0.25 0.68
-Blocker 0.49 0.14 0.52 0.09 0.54
Ca-blocker 0.94 0.86 0.92 0.83 0.37
ARB/ACE 0.68 0.93 0.07 0.84 0.56
Statin 0.74 0.09 0.64 0.56 0.75
Fibrate 0.78 0.26 0.57 0.59 0.88
Nicorandil 0.18 0.54 0.34 0.66 0.07
Nitrate <0.05 0.11 0.18 0.59 0.84
Diuretics 0.86 0.82 0.99 0.91 0.58
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aPOBA: plain old balloon angioplasty; CB: cutting balloon ang
converting enzyme inhibitor.
On the other hand, histamine exerts inotropic
effects via H2-receptors, such as enhancing ven-
tricular contraction and increasing the sinus rate.
Several adverse effects such as bradycardia, sinus
arrest, atrio-ventricular conduction disturbances,
and cardiac decompensation have been linked to
the use of H2-blockers [4]. However, these mostly
show spontaneous recovery. These effects occurred
on intravenous administration at a very high-dose
(more than 100mg on in a single bolus). In general,
changes in cardiac performance are modulated
by the autonomic nervous system, and physiolog-
ical homeostasis is preserved. Therefore, changes
in autonomic nervous activity and/or sympathova-
gal balance may be involved in the cardiovascular
effects. Further, cardiovascular effects of H2-
t
a
isty; ARB: angiotensin II receptor blocker; ACE: angiotensin
locker may be related to the autonomic nervous
ystem, and modulated activity, and/or sympatho-
agal balance [5].
In previous reports, PPI and H2-blocker
ecreased cardiac function, but controversy
xisted. Although our study compared pre and
ollow-up PCI, the cardiac function showed no
arked changes on long-term administration. In
schemic heart disease patient, other medicines
uch as -blocker, Ca-blocker, or diuretics have a
trong effect, and PPI and H2-blocker would have
weak inﬂuence on cardiac function.
Aspirin and other anti-platelet drugs are essen-
ial for patients with ischemic heart disease [1,2],
nd when physicians or patients are anxious regard-
ng the weak adverse effects of PPI or H2-blocker
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n cardiac function, and cease to take these drugs,
he risk of NSAIDs-related peptic ulcer is high [3].
n the presence of an active ulcer, anti-platelet
rugs must be discontinued in some patients. In
his case, the risks of cardiac event such as stent
hrombus are increased [2], particularly in patients
ndergoing drug eluting stent implantation [9,10].
dditionally, patients with ischemic heart disease
xhibit multiple disorders such as hypertension,
iabetes mellitus and chronic kidney disease. A
ow hemoglobin level together with chronic kid-
ey disease increases the risk of coronary heart
isease-related death [16]. Attempts should be
ade in patients with ischemic heart disease and
hronic kidney disease to reduce the risk of anemia,
uch as protecting against gastro-intestinal hem-
rrhage. To prevent NSAIDs-related, ulcer should
e used PPI or H2-blocker should be adminis-
ered.
In conclusion, the long-term administration of
PI and high-dose H2-blocker does not marked alter
ardiac function. Cardiologists should not hesitate
o use them, due to concerns over any cardiac func-
ion inhibitory effect.
tudy limitations
his study had several important limitations. It was
retrospective, non-randomized study in which the
tudy population was small and the results reﬂect
he experience of only a single center. It, there-
ore, lacks the obvious advantages of a larger,
ulticenter, multinational randomized study. Inclu-
ion criteria of this study were too restrictive to
imit number of the study patients. This led that
he present study might be underpowered for the
etection of the changes by PPI or H2-blocker.
owever, most patients with coronary heart dis-
ase who had a prior cardiac catheterization
tudy had already administrated PPI or H2-blocker.
dditionally cardiac function of patients prior
evascularization with unstable angina, myocar-
ial infarction, congestive heart failure could be
reatly affected by revascularization or other drugs
uch as - and Ca-blocker, diuretics, and ARB/ACE.
o investigate effects of PPI or H2-blocker, these
ases might have bias in a single-center expe-
ience. It is important issue which could affect
he clinical practice for patients with coronary
eart disease receiving PPI or H2-blocker for pre-
ention of such aspirin- or NSAIDs-related peptic
lcers. Therefore, it should be investigated in a
urther study of larger, multicenter, multinational
andomized study including patients with LV dys-
unction.
[
[47
We recorded LV pressure with a pig-tail catheter,
nd dp/dt values lacked the accuracy of those mea-
ured using a micro-manometer-tipped catheter.
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